Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.

Richard M BergenstalAthena Philis-TsimikasCarol H WyshamMolly C CarrJuliana M Bue-Valleskey Fady T Botros Thomas Blevins Julio Rosenstock

Published in: Diabetes, obesity & metabolism (2024)

The QWINT development programme includes a racially and geographically diverse population to provide important information regarding the efficacy and safety of efsitora and its clinical management of people with diabetes.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
study protocol
clinical trial
healthcare
randomized controlled trial
metabolic syndrome
skeletal muscle
double blind